Kinnate Biopharma Inc.

NASDAQ: KNTE · Real-Time Price · USD
2.65
-0.01 (-0.38%)
At close: Apr 02, 2024, 8:00 PM

Company Description

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States.

The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.

The company was incorporated in 2018 and is headquartered in San Francisco, California.

Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Kinnate Biopharma Inc.
Kinnate Biopharma Inc. logo
Country United States
IPO Date Dec 3, 2020
Industry Biotechnology
Sector Healthcare
Employees 84
CEO Nima Farzan M.B.A.

Advertisement

Contact Details

Address:
103 Montgomery Street
San Francisco, California
United States
Website https://www.kinnate.com

Stock Details

Ticker Symbol KNTE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001797768
CUSIP Number 49705R105
ISIN Number US49705R1059
Employer ID 82-4566526
SIC Code 2834

Key Executives

Name Position
Nima Farzan M.B.A. President, Chief Executive Officer & Director
Mark A. Meltz Chief Operating Officer, General Counsel, Treasurer & Secretary
Neha Krishnamohan Chief Financial Officer, Principal Accounting Officer and Executive Vice President of Corporate Development
Dr. Richard Thomas Williams MBBS, Ph.D. Chief Medical Officer
Dr. Robert Kania Ph.D. Senior Vice President of Research

Latest SEC Filings

Date Type Title
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Apr 17, 2024 15-12G Filing
Apr 05, 2024 4 Filing
Apr 05, 2024 4 Filing
Apr 05, 2024 4 Filing
Apr 05, 2024 4 Filing
Apr 05, 2024 4 Filing
Apr 05, 2024 4 Filing
Apr 05, 2024 4 Filing
Apr 05, 2024 4 Filing